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Lamiaux and colleagues [1] found that 19% of the
patients treated with BRAF/MEK inhibitors (BRAFi/
MEKi) after previous immunotherapy (IT) may present a
severe skin rash (grade ≥ 3), even complicated by sys-
temic involvement and organ damage. Among the 10
cases of severe skin toxicity, eight patients had received
previous IT, whereas the median time of onset was
12 days after the treatment initiation of BRAFi/MEKi. In
four patients with kidney, liver, and heart involvement,
the symptoms were interpreted as part of a systemic
reaction [drug rash with eosinophilia, and systemic
symptoms (DRESS)]; yet, the DRESS criteria were only
partially fulfilled and no peripheral eosinophilia was
reported. Patients were treated with local and intrave-
nous steroids. The systemic treatment with BRAFi/
MEKi was, in most of the cases, discontinued
permanently.
We have previously reported four cases of cytokine
release syndrome (CRS) during the sequential use of
BRAFi/MEKi after immune checkpoint blockade with
severe (grade ≥ 3) skin and systemic involvement [2,3].
The constellation of the symptoms described in our
cases, which included among all and except for pyrexia
and maculopapular rash also a transaminitis, an uncom-
mon event during treatment with BRAFi/MEKi, fulfills
the diagnosis of a CRS. The documented, high circulat-
ing cytokine levels, including interleukin-6 (IL-6), tumor
necrosis factor-α, and interferon-γ, further confirm our
hypothesis. These clinical cases underline the complex-
ity of the immunologic interactions caused during the
sequential therapy with immune checkpoint inhibitors
and kinase inhibitors. These manifestations should be
distinguished from a hypersensitivity syndrome to the
kinase inhibitors (DRESS); the lack of the frequently
observed eosinophilia of DRESS as well as other blood
abnormalities, reactivation of human herpes virus 6, or
lymphadenopathy do not support the diagnosis. The
short onset of the symptoms after the treatment initiation
(in our cases, the median time was 10 days) and the tol-
erance of the identical medication after reinduction are
also typical for a systemic inflammatory reaction and
untypical for a DRESS. Besides, a lymphocyte transfor-
mation test performed on one of our patients was nega-
tive. We attribute this systemic reaction to an aberrant
release of proinflammatory cytokines, mainly accom-
panied by symptoms such as pyrexia, transaminitis, renal
insufficiency, and maculopapular skin rash. Thus, such
episodes have also been reported in the preliminary
findings of a phase III clinical trial with dabrafenib, tra-
metinib, and anti-PD1 (NCT02967692) [4].
We suggest a ‘cytokine storm’ as a possible mechanism of
the CRS because of a high level of immune activation in
the context of the simultaneous presence of immune
checkpoint and MAPK pathway inhibition. Targeting
oncogenic drivers in the immune system leads to a T-cell
activation and consecutive release of cytokines, such as
tumor necrosis factor-α and interferon-γ, with further
activation of innate immune cells and production of
numerous cytokines, among all also IL-6, which impor-
tantly causes a positive feedback loop, leading to a
‘cytokine storm’ [5]. However, clinical and preclinical
data propose that MAPK pathway inhibition may
enhance T-cell activation through an increase of proin-
flammatory cytokines and cytotoxic factors [6]. These
changes to the tumor microenvironment would be
expected to increase efficacy by making tumors more
susceptible to IT.
We therefore propose CRS as an important and severe
differential diagnosis in patients with severe rash and
systemic symptoms during the sequential treatment of
targeted therapy and IT. The clear description of our
cases along with the successful use of tocilizumab (anti-
IL-6 agent) suggests that CRS is a severe manifestation
occurring early during the initiation of targeted therapy
after the treatment of IT in patients with metastatic
melanoma. As the management and treatment of the
CRS can be very challenging, we advise the practitioners
to measure the cytokine levels and use cytokine
antagonists as potential therapeutic candidates in cases
refractory to steroids.
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